Is there a generic for the migraine drug nurtec odt?

When Will a Generic Nurtec ODT Be Available?

Nurtec ODT is an orally disintegrating tablet for the acute treatment of migraines. The generic version of Nurtec ODT, which is a bioequivalent version of the branded medication, has yet to enter the market.

Why Are Companies Not Challenging Nurtec ODT's Patent?

The manufacturer, Biohaven Pharmaceuticals, holds a patent for Nurtec ODT that extends until 2028 in the United States [1]. With this patent protection, the company has a significant marketing exclusive period to maintain sales and profit.

Are There Any Biosimilars for Nurtec ODT?

To date, no biosimilar for Nurtec ODT has been approved by the FDA. Biosimilars are biologic medications that are highly similar to the original product and have undergone rigorous testing to demonstrate their efficacy and safety. Since the patent for Nurtec ODT is still in effect, no biosimilar version has been approved yet.

What Are the Implications of No Generic Nurtec ODT?

The absence of an immediate generic version of Nurtec ODT means that consumers may continue to rely on the branded medication for relief from migraine symptoms. This can lead to higher costs for patients and payers, as the manufacturer has more pricing flexibility due to its patent protection.

Patent Expiration and Generic Availability

The patent for Nurtec ODT is set to expire in 2028. Once the patent expires, generic manufacturers will be able to produce and market their own versions of the medication without needing to obtain licensing or permission from the brand owner. At that point, patients may have access to more affordable generic versions [2].

Sources:

[1] Biohaven Pharmaceuticals. (n.d.). Nurtec ODT. Retrieved from https://www.biohavenpharma.com/assets/uploads/files/PI-BHV-2028_1.pdf

[2] DrugPatentWatch. (n.d.). Nurtec ODT. Retrieved from https://www.drugpatentwatch.com/patent/Us7833829/